Impact of EZH2 polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic features

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Yu, Yung Luen ^a,b   Su, Kuo Jung ^a   Hsieh, Ming Ju ^c,d   Wang, Shian Shiang ^c,e   Wang, Po Hui ^c,f   Weng, Wei Chun ^g   Yang, Shun Fa ^c,f  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b ASIA UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^e TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^f CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; TRANSCRIPTION FACTOR EZH2; EZH2 PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2;

ADULT; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CLINICAL FEATURE; CONTROLLED STUDY; EZH2 GENE; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HISTOPATHOLOGY; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CARCINOMA; AGED; ALLELE; BLADDER TUMOR; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PATHOLOGY; UROTHELIUM;

ADULT; AGED; ALLELES; CARCINOMA, TRANSITIONAL CELL; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYCOMB REPRESSIVE COMPLEX 2; POLYMORPHISM, SINGLE NUCLEOTIDE; TAIWAN; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84898657458     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093635     Document Type: Article

References (31)

1. Gu J, Wu X (2011) Genetic susceptibility to bladder cancer risk and outcome. Per Med 8: 365-374.
2. Aben KK, Witjes JA, Schoenberg MP, Hulsbergen-van de Kaa C, Verbeek AL, et al. (Pubitemid 34150813)
3. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, et al. (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 59: 1009-1018.
4. Lauss M, Aine M, Sjodahl G, Veerla S, Patschan O, et al. (2012) DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status. Epigenetics 7: 858-867.
5. Hinz S, Kempkensteffen C, Christoph F, Hoffmann M, Krause H, et al. (2008) Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder. J Cancer Res Clin Oncol 134: 331-336. (Pubitemid 351170054)
6. Esteller M (2007) Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 16 Spec No 1: R50-59. (Pubitemid 47241842)
7. Hansen KD, Timp W, Bravo HC, Sabunciyan S, Langmead B, et al. (2011) Increased methylation variation in epigenetic domains across cancer types. Nat Genet 43: 768-775.
8. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, et al. (2007) Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39: 232-236. (Pubitemid 46184355)
9. Heyn H, Esteller M (2013) EZH2: an epigenetic gatekeeper promoting lymphomagenesis. Cancer Cell 23: 563-565.
10. Simon JA, Lange CA (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647: 21-29.
11. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, et al. (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100: 11606-11611. (Pubitemid 37205983)
12. Ren G, Baritaki S, Marathe H, Feng J, Park S, et al. (2012) Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res 72: 3091-3104.
13. Sauvageau M, Sauvageau G (2010) Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 7: 299-313.
14. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, et al. (2008) Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27: 7274-7284.
15. Di Paolo A, Danesi R, Del Tacca M (2004) Pharmacogenetics of neoplastic diseases: new trends. Pharmacol Res 49: 331-342. (Pubitemid 38175330)
16. Shastry BS (2002) SNP alleles in human disease and evolution. J Hum Genet 47: 561-566. (Pubitemid 36083255)
17. Crea F, Fornaro L, Paolicchi E, Masi G, Frumento P, et al. (2012) An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Ann Oncol 23: 1207-1213.
18. Yoon KA, Gil HJ, Han J, Park J, Lee JS (2010) Genetic polymorphisms in the polycomb group gene EZH2 and the risk of lung cancer. J Thorac Oncol 5: 10-16.
19. Yu YL, Wei CW, Chen YL, Chen MH, Yiang GT (2010) Immunotherapy of breast cancer by single delivery with rAAV2-mediated interleukin-15 expression. Int J Oncol 36: 365-370.
20. Yiang GT, Harn HJ, Yu YL, Hu SC, Hung YT, et al. (2009) Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice. J Biomed Sci 16: 47.
21. Wu CS, Yen CJ, Chou RH, Li ST, Huang WC, et al. (2012) Cancer-associated carbohydrate antigens as potential biomarkers for hepatocellular carcinoma. PLoS One 7: e39466.
22. Yu YL, Su KJ, Chen CJ, Wei CW, Lin CJ, et al. (2012) Synergistic anti-tumor activity of isochaihulactone and paclitaxel on human lung cancer cells. J Cell Physiol 227: 213-222.
23. Cantone I, Fisher AG (2013) Epigenetic programming and reprogramming during development. Nat Struct Mol Biol 20: 282-289.
24. Yu YL, Chou RH, Wu CH, Wang YN, Chang WJ, et al. (2012) Nuclear EGFR suppresses ribonuclease activity of polynucleotide phosphorylase through DNAPK-mediated phosphorylation at serine 776. J Biol Chem 287: 31015-31026.
25. Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, et al. (2005) Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 11: 8570-8576. (Pubitemid 43005902)
26. Arisan S, Buyuktuncer ED, Palavan-Unsal N, Caskurlu T, Cakir OO, et al. (2005) Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol Int 75: 252-257. (Pubitemid 41433876)
27. Chung TT, Pan MS, Kuo CL, Wong RH, Lin CW, et al. (2011) Impact of RECK gene polymorphisms and environmental factors on oral cancer susceptibility and clinicopathologic characteristics in Taiwan. Carcinogenesis 32: 1063-1068.
28. International HapMap C (2003) The International HapMap Project. Nature 426: 789-796.
29. Cardoso C, Mignon C, Hetet G, Grandchamps B, Fontes M, et al. (2000) The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders. Eur J Hum Genet 8: 174-180. (Pubitemid 30189860)
30. Chung YT, Hsieh LL, Chen IH, Liao CT, Liou SH, et al. (2009) Sulfotransferase 1A1 haplotypes associated with oral squamous cell carcinoma susceptibility in male Taiwanese. Carcinogenesis 30: 286-294.
31. Hosking L, Lumsden S, Lewis K, Yeo A, McCarthy L, et al. (2004) Detection of genotyping errors by Hardy-Weinberg equilibrium testing. Eur J Hum Genet. 12: 395-399. (Pubitemid 38660191)